首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy

【24h】

Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy

机译：REGN1979（一种抗CD20 x抗CD3双特异性单克隆抗体）在先前用CD20定向抗体疗法治疗的CD20 + B细胞恶性肿瘤患者中的1期研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2016年第22期|共6页
作者
Bannerji Rajat; Brown Jennifer R.; Advani Ranjana H.; Arnason Jon; OBrien Susan M.; Allan John N.; Chavez Julio C.; Barnes Jeffrey A.; Joyce Robin; Ansell Stephen; Topp Max S.; Adriaens Lieve; Ufkin Melanie; Kostic Ana; Paccaly Anne; Gao Bo; Trail Pamela A.; Lowy Israel; Brownstein Carrie;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy [J] . Bannerji Rajat, Brown Jennifer R., Advani Ranjana H., Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：REGN1979（一种抗CD20 x抗CD3双特异性单克隆抗体）在先前用CD20定向抗体疗法治疗的CD20 + B细胞恶性肿瘤患者中的1期研究
2. PHARMACOKINETICS AND EXPOSURE-RESPONSE FOR REGN1979, A BISPECIFIC ANTI-CD20 X ANTI-CD3 ANTIBODY, IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA. [J] . Yang F., Zhu M., Toroghi M., Clinical Pharmacology and Therapeutics . 2020,第S1期

机译：患有非霍奇金淋巴瘤患者的药代动力学和REGN1979的曝光响应，是非霍奇金淋巴瘤患者的抗CD20 x抗CD3抗体。
3. Emerging Clinical Activity of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL), and Other B-Cell Non-Hodgkin Lymphoma (B-NHL) Subtypes [J] . Bannerji Rajat, Arnason Jon E., Advani Ranjana, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：RegN1979的临床活性，抗CD20 x抗CD3双特异性抗体，复发/难治滤泡淋巴瘤（FL），弥漫性大B细胞淋巴瘤（DLBCL）和其他B细胞非霍奇金淋巴瘤（B. -NHL）亚型
4. 188Re-labeled anti-CD20 monoclonal antibody: Labeling and quality controlstudies [C] . R.Leyva Monta?a, I.Hernández González, M.Zamora Barrabí, Trends in Radiopharmaceuticals(ISTR-2005) . 2007

机译：188重新标记的抗CD20单克隆抗体：标记和质量控制研究
5. Mechanisms of immune regulation by FcR non-binding anti-CD3 monoclonal antibodies. [D] . Smith, Judith Anne. 1997

机译：FcR非结合抗CD3单克隆抗体的免疫调节机制。
6. Immunotherapy with FBTA05 (Bi20) a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven open-label non-randomized uncontrolled dose-escalating Phase I/II-trial [O] . Raymund Buhmann, Stanglmaier Michael, Hess Juergen, 2013

机译：同种异体干细胞移植后复发或难治性B细胞淋巴瘤中使用三功能双特异性抗CD3 x抗CD20抗体FBTA05（Bi20）和供体淋巴细胞输注（DLI）进行免疫治疗：研究者驱动的开放标签研究方案非随机不受控制剂量递增的I / II试验阶段
7. Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial [O] . 2013

机译：同种异体干细胞移植后复发或难治性B细胞淋巴瘤中使用三功能双特异性抗CD3 x抗CD20抗体FBTA05（Bi20）和供体淋巴细胞输注（DLI）进行免疫治疗：研究者驱动的开放标签研究方案，非随机，不受控制，剂量递增的I / II试验阶段
8. Monoclonal Antibodies and Cancer. Studies on the Use of Monoclonal Antibodies for Imaging and Therapy of Cancer, with Special Emphasis on Ovarian Carcinoma [R] . Haisma, H. J. 1987

机译：单克隆抗体和癌症。单克隆抗体在癌症成像和治疗中的应用研究，特别强调卵巢癌

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号